Vlado Perkovic Tweets That They Are Stopping FLOW Early for Efficacy We will have to wait for the presentation and publication of the manuscript to fully understand the details and cost-benefit implications of semaglutide in chronic kidney disease (CKD), but this result was not unexpected
Insert the needle with a quick, dart-like motion
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model
While clinical trials show greater average weight loss at 2.4 mg compared to lower doses, individual responses vary widely
Semaglutide reduced systolic blood pressure by 3.3 mm Hg, high-sensitivity C-reactive protein by 37.8%, and improved lipid profilesall achieved on top of high baseline rates of evidence-based cardiovascular therapies (90% on statins, 86% on antiplatelet agents).[1] These pleiotropic effects likely contribute to cardiovascular risk reduction through mechanisms distinct from adiposity changes, supporting the reconceptualization of GLP-1 receptor agonists as cardiovascular disease-modifying agents rather than simply weight-loss medications
